Lantern Pharma Reports Phase 2 HARMONIC Trial Data Showing LP-300 Benefit in EGFR-Mutant Lung Cancer
Lantern Pharma announced updated Phase 2 data for LP-300 in EGFR L858R-mutant non-small cell lung cancer, showing improved progression-free survival and a clean safety profile, with an FDA-cleared protocol amendment extending dosing to eight cycles.
Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, reported updated Phase 2 HARMONIC trial data demonstrating that LP-300, in combination with carboplatin and pemetrexed, provided a progression-free survival (PFS) benefit that increased with treatment duration in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer (NSCLC) who had progressed following tyrosine kinase inhibitor (TKI) therapy. The emerging data showed a median PFS of 8.9 months among L858R patients treated through up to six cycles, compared with 8.4 months across the overall L858R cohort, while maintaining what the company described as an exceptionally clean safety and tolerability profile.
The results support a recently FDA-cleared protocol amendment extending LP-300 dosing from six to eight cycles. This is particularly significant for the L858R subgroup, which represents a substantial portion of EGFR-mutant NSCLC patients and often has limited treatment options after TKI failure. The extension could allow patients to derive greater benefit from the therapy.
Lantern Pharma is leveraging its proprietary RADR platform to transform the development of cancer therapies. The company's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
Additionally, Lantern has commercialized its multi-agentic AI co-scientist platform, withZeta.ai, as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. For more information, visit the company's newsroom at https://ibn.fm/LTRN.
These developments are important because they address an unmet need in EGFR L858R-mutant NSCLC, where patients often develop resistance to TKIs. The clean safety profile and potential for extended dosing could position LP-300 as a valuable treatment option. The AI-driven approach also highlights the growing role of computational methods in oncology drug development.